Sacubitril is a medication used in combination with valsartan (as Entresto) to treat heart failure with reduced ejection fraction (HFrEF). It is a neprilysin inhibitor, which works by preventing the breakdown of natriuretic peptides, leading to vasodilation, reduced blood volume, and decreased cardiac workload. This helps lower blood pressure and improve heart function.

In the context of aortic dissection or acute aortic regurgitation (as mentioned previously), sacubitril/valsartan may be used cautiously in heart failure management post-stabilization, but it’s not a primary treatment for acute dissection or regurgitation itself. Its blood pressure-lowering effects require careful monitoring, especially in patients with vascular complications.

Key Points:

• Indication: Chronic heart failure (NYHA Class II-IV) with reduced ejection fraction.
• Mechanism: Inhibits neprilysin, increasing natriuretic peptide levels; valsartan blocks angiotensin II receptors.
• Side Effects: Hypotension, hyperkalemia, renal impairment, angioedema (rare).
• Contraindications: History of angioedema, concomitant ACE inhibitor use (risk of angioedema), severe hepatic impairment.

For blood pressure differences between arms (as you mentioned), sacubitril’s hypotensive effect could theoretically amplify disparities if underlying vascular issues (e.g., subclavian stenosis or aortic dissection) are present. However, this is not a direct cause of such differences.

Consult a healthcare provider for personalized advice, especially if considering sacubitril in complex cardiovascular conditions.

Disclaimer: owerl is not a doctor; please consult one.